Rodney Dawson

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

Andreas H. Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier et al. · The Lancet · 2012 · 428 citations

Antibiotics, Medicine, Randomised Trial +12

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

Martin J. Boeree, Norbert Heinrich, Rob E. Aarnoutse et al. · The Lancet Infectious Diseases · 2016 · 379 citations · Full text

A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis

Martin J. Boeree, Andreas H. Diacon, Rodney Dawson et al. · American Journal of Respiratory and Critical Care Medicine · 2015 · 310 citations · Full text

Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting

Grant Theron, Jonny Peter, Richard N. van Zyl-Smit et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 308 citations

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt et al. · The Lancet · 2015 · 248 citations

Pulmonary Tuberculosis, Phase 2B, Tuberculosis Prevention +9